The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Big Pharma Split's share price is C$11.61.
Big Pharma Split's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was C$4.27. Hence, Big Pharma Split's PS Ratio for today is 2.72.
Good Sign:
Big Pharma Split Corp stock PS Ratio (=2.56) is close to 10-year low of 2.35.
The historical rank and industry rank for Big Pharma Split's PS Ratio or its related term are showing as below:
TSX:PRM'
s PS Ratio Range Over the Past 10 Years
Min: 2.35 Med: 6.07 Max: 58.57
Current: 2.72
During the past 9 years, Big Pharma Split's highest PS Ratio was 58.57. The lowest was 2.35. And the median was 6.07.
TSX:PRM's PS Ratio is not ranked
in the Asset Management industry.
Industry Median: 7.37
vs TSX:PRM: 2.72
During the past 12 months, the average Revenue per Share Growth Rate of Big Pharma Split was 1093.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 22.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 9 years, Big Pharma Split's highest 3-Year average Revenue per Share Growth Rate was 25.50% per year. The lowest was -55.00% per year. And the median was -5.75% per year.
Back to Basics: PS Ratio
Big Pharma Split (TSX:PRM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Big Pharma Split PS Ratio Related Terms
Big Pharma Split PS Ratio Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, Big Pharma Split's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split PS Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's PS Ratio distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Big Pharma Split's Share Price of today is C$11.61.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Big Pharma Split's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was C$4.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Big Pharma Split (TSX:PRM) has a PS Ratio of 2.72 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Big Pharma Split and its competitors. This is 55% below median its historical median of 6.07. Over the past decade, Big Pharma Split's PS Ratio has ranged from 2.35 to 58.57.
Is Big Pharma Split's PS Ratio too high?
Big Pharma Split's current PS Ratio of 2.72 is 55% below median its 10-year median of 6.07. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 58.57. The Asset Management industry median PS Ratio is 7.37. Big Pharma Split's value of 2.72 is 63.1% below this industry median. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's PS Ratio compare to BLK and BX?
Big Pharma Split's PS Ratio of 2.72 can be compared against companies in the Asset Management industry. The industry median PS Ratio is 7.37. Big Pharma Split's value of 2.72 is 63.1% below this benchmark. Historically, Big Pharma Split's own PS Ratio has ranged from 2.35 to 58.57 over the past decade. While the company's 10-year median is 6.07 vs. the industry median of 7.37, Big Pharma Split has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for an Asset Management company?
The median PS Ratio among Asset Management companies is 7.37, based on 1,406 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Big Pharma Split's current PS Ratio of 2.72 is 63.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median PS Ratio is 7.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current PS Ratio is 2.72, which is 55% below median its own 10-year median of 6.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current PS Ratio of 2.72. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current PS Ratio is 2.72, which is 55% below median its 10-year median of 6.07 and 63.1% below the Asset Management industry median of 7.37. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current PS Ratio is 2.72 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
PS Ratio: 2.72 (55% below median its 10-year median of 6.07)
GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
Industry Position: 63.1% below the Asset Management median
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score
Get the complete analysis for TSX:PRM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
